Heather Hampel

List of Publications by Year
in descending order

214 papers	20,394 citations	11651 70 h-index	11052 137 g-index
224 all docs	224 docs citations	224 times ranked	16348 citing authors

#	Article	IF	Citations
1	Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). New England Journal of Medicine, 2005, 352, 1851-1860.	27.0	1,237
2	ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. American Journal of Gastroenterology, 2015, 110, 223-262.	0.4	1,204
3	Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 5783-5788.	1.6	760
4	Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics, 1997, 17, 79-83.	21.4	630
5	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	1.6	603
6	Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 2006, 66, 7810-7817.	0.9	564
7	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncology, 2017, 3, 464.	7.1	510
8	The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. Gastroenterology, 2008, 135, 419-428.e1.	1.3	480
9	Identification of Lynch Syndrome Among Patients With Colorectal Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 1555.	7.4	443
10	Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.. Journal of Clinical Oncology, 1998, 16, 2417-2425.	1.6	435
11	EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 2009, 11, 42-65.	2.4	431
12	A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine, 2015, 17, 70-87.	2.4	418
13	Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 15044-15049.	7.1	399
14	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	21.4	377
15	Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Syndrome: Later Age of Onset. Gastroenterology, 2005, 129, 415-421.	1.3	338
16	Microsatellite Instability Detection by Next Generation Sequencing. Clinical Chemistry, 2014, 60, 1192-1199.	3.2	333
17	Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. Journal of the National Cancer Institute, 2010, 102, 193-201.	6.3	328
18	Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations. Gastroenterology, 2014, 147, 1308-1316.e1.	1.3	328

#	Article	IF	Citations
19	Cancer Risk in Hereditary Nonpolyposis Colorectal Cancer Syndrome: Later Age of Onset. Gastroenterology, 2005, 129, 415-421.	1.3	309
20	Germline PTEN Promoter Mutations and Deletions in Cowden/Bannayan-Riley-Ruvalcaba Syndrome Result in Aberrant PTEN Protein and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway. American Journal of Human Genetics, 2003, 73, 404-411.	6.2	283
21	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics, 1996, 13, 126-128.	21.4	282
22	Clinical Relevance of Microsatellite Instability in Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 3380-3387.	1.6	273
23	Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation. American Journal of Pathology, 2000, 157, 1123-1128.	3.8	254
24	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	4.9	253
25	The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine, 2010, 12, 93-104.	2.4	250
26	Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes*. American Journal of Human Genetics, 2001, 69, 704-711.	6.2	236
27	Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet, The, 2001, 358, 210-211.	13.7	210
28	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	12.8	193
29	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1032-1041.	4.9	191
30	Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1010-1030.	4.9	179
31	Functional Significance and Clinical Phenotype of Nontruncating Mismatch Repair Variants of MLH1. Gastroenterology, 2005, 129, 537-549.	1.3	170
32	Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 4301-4308.	1.6	163
33	Germline Allele-Specific Expression of TGFBR1 Confers an Increased Risk of Colorectal Cancer. Science, 2008, 321, 1361-1365.	12.6	157
34	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	2.4	153
35	The Frequency of Muir-Torre Syndrome Among Lynch Syndrome Families. Journal of the National Cancer Institute, 2008, 100, 277-281.	6.3	152
36	Mismatch Repair Gene PMS2. Cancer Research, 2004, 64, 4721-4727.	0.9	149

#	Article	IF	Citations
37	Cancer Risks for PMS2-Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	1.6	147
38	Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet, The, 1996, 347, 1643-1645.	13.7	145
39	The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means?. Cancer Prevention Research, 2011, 4, 1-5.	1.5	138
40	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncology, 2018, 4, 806.	7.1	136
41	Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A stateâ€ofâ€theâ€science review. Cancer, 2016, 122, 2633-2645.	4.1	131
42	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	6.2	124
43	Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. Journal of Clinical Oncology, 2017, 35, 2568-2575.	1.6	122
44	Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Journal of Genetic Counseling, 2012, 21, 484-493.	1.6	119
45	The Founder Mutation MSH2*1906Gâ†'C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population. American Journal of Human Genetics, 2002, 71, 1395-1412.	6.2	118
46	NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 939-949.	4.9	116
47	Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. Health Affairs, 2018, 37, 801-808.	5.2	114
48	Cumulative Burden of Colorectal Cancerâ€"Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	1.3	110
49	Characteristics of Early-Onset vs Late-Onset Colorectal Cancer. JAMA Surgery, 2021, 156, 865.	4.3	110
50	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1465-1475.	4.9	109
51	Genetic Testing for Cancer Predisposition. Annual Review of Medicine, 2001, 52, 371-400.	12.2	103
52	Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecologic Oncology, 2009, 114, 128-134.	1.4	97
53	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nature Communications, 2017, 8, 14755.	12.8	96
54	Long-range PCR facilitates the identification ofPMS2-specific mutations. Human Mutation, 2006, 27, 490-495.	2.5	90

#	Article	IF	Citations
55	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20.	1.3	90
56	Functional Significance and Clinical Phenotype of Nontruncating Mismatch Repair Variants of. Gastroenterology, 2005, 129, 537-549.	1.3	89
57	Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 2007, 67, 9603-9603.	0.9	88
58	Prostate cancer incidence in males with Lynch syndrome. Genetics in Medicine, 2014, 16, 553-557.	2.4	88
59	Identification and characterization of genomic rearrangements ofMSH2 andMLH1 in Lynch syndrome (HNPCC) by novel techniques. Human Mutation, 2003, 22, 258-258.	2.5	87
60	Somatic Acquisition and Signaling of <EMPH TYPE="ITAL">TGFBR1</EMPH>*6A in Cancer. JAMA - Journal of the American Medical Association, 2005, 294, 1634.	7.4	87
61	Biallelic MUTYH mutations can mimic Lynch syndrome. European Journal of Human Genetics, 2014, 22, 1334-1337.	2.8	87
62	Genetic counseling and cascade genetic testing in Lynch syndrome. Familial Cancer, 2016, 15, 423-427.	1.9	84
63	Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 2012, 14, 152-162.	2.4	83
64	Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1538-1575.	4.9	82
65	Colorectal Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 959-968.	4.9	80
66	Improving performance of multigene panels for genomic analysis of cancer predisposition. Genetics in Medicine, 2016, 18, 974-981.	2.4	80
67	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecologic Oncology, 2017, 146, 588-595.	1.4	77
68	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396.	5.5	76
69	Gi Polyposis and Glycogenic Acanthosis of The Esophagus Associated With Pten Mutation Positive Cowden Syndrome in The Absence of Cutaneous Manifestations. American Journal of Gastroenterology, 2003, 98, 1429-1434.	0.4	75
70	A Founder Mutation of the <EMPH TYPE="ITAL">MSH2</EMPH> Gene and Hereditary Nonpolyposis Colorectal Cancer in the United States. JAMA - Journal of the American Medical Association, 2004, 291, 718.	7.4	75
71	Evidence for heritable predisposition to epigenetic silencing of MLH1. International Journal of Cancer, 2007, 120, 1684-1688.	5.1	75
72	Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 101-109.	3.8	73

#	Article	IF	Citations
73	Hereditary colorectal cancer: risk assessment and management. Clinical Genetics, 2001, 58, 89-97.	2.0	68
74	Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology, 2009, 114, 486-490.	1.4	68
75	NCCN GuidelinesÂ® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1122-1132.	4.9	68
76	Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. Health Affairs, 2016, 35, 1367-1373.	5.2	67
77	Novel germlineCDH1mutations in hereditary diffuse gastric cancer families. Human Mutation, 2002, 19, 518-525.	2.5	63
78	Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients. Obstetrics and Gynecology, 2009, 114, 530-536.	2.4	62
79	Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genetics in Medicine, 2014, 16, 773-782.	2.4	62
80	Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome. Journal of Medical Genetics, 2019, 56, 462-470.	3.2	61
81	Pathogenicity of MSH2 Missense Mutations Is Typically Associated With Impaired Repair Capability of the Mutated Protein. Gastroenterology, 2006, 131, 1408-1417.	1.3	59
82	How do we approach the goal of identifying everybody with Lynch Syndrome?. Familial Cancer, 2013, 12, 313-317.	1.9	58
83	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	10.7	58
84	Qualitative Comparative Analysis. Journal of Mixed Methods Research, 2016, 10, 251-272.	2.6	57
85	Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Modern Pathology, 2018, 31, 1891-1900.	5.5	57
86	Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. Journal of Medical Genetics, 2022, 59, 318-327.	3.2	57
87	Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer. Obstetrics and Gynecology, 2006, 108, 1208-1215.	2.4	56
88	Point: Justification for Lynch Syndrome Screening Among All Patients With Newly Diagnosed Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 597-601.	4.9	56
89	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
90	Use of Whole Genome Sequencing for Diagnosis and Discovery in the Cancer Genetics Clinic. EBioMedicine, 2015, 2, 74-81.	6.1	50

#	Article	IF	Citations
91	Lynch Syndrome Limbo: Patient Understanding of Variants of Uncertain Significance. Journal of Genetic Counseling, 2017, 26, 866-877.	1.6	50
92	Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Human Pathology, 2006, 37, 831-838.	2.0	49
93	Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. International Journal of Colorectal Disease, 2010, 25, 703-712.	2.2	48
94	A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. Journal of Medical Genetics, 2008, 45, 340-345.	3.2	47
95	BRAF V600E Mutation Analysis Simplifies the Testing Algorithm for Lynch Syndrome. American Journal of Clinical Pathology, 2013, 140, 177-183.	0.7	46
96	Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. Gastroenterology, 2015, 149, 1446-1453.	1.3	46
97	Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genetics in Medicine, 2009, 11, 812-817.	2.4	45
98	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	12.1	44
99	Immunodepletion Plasma Proteomics by TripleTOF 5600 and Orbitrap Elite/LTQ-Orbitrap Velos/Q Exactive Mass Spectrometers. Journal of Proteome Research, 2013, 12, 4351-4365.	3.7	43
100	Prevalence of Germline Mutations in Polyposis and Colorectal Cancerâ€“Associated Genes in Patients With Multiple Colorectal Polyps. Clinical Gastroenterology and Hepatology, 2019, 17, 2008-2015.e3.	4.4	43
101	Endometrial cancer patients and compliance with genetic counseling: Room for improvement. Gynecologic Oncology, 2011, 123, 532-536.	1.4	40
102	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genetics in Medicine, 2012, 14, 670-680.	2.4	40
103	Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family. Stem Cell Reports, 2013, 1, 336-349.	4.8	40
104	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	1.6	40
105	Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Familial Cancer, 2020, 19, 223-239.	1.9	39
106	Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Familial Cancer, 2016, 15, 253-260.	1.9	36
107	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology, 2016, 151, 440-447.e1.	1.3	36
108	Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. American Journal of Human Genetics, 2018, 103, 19-29.	6.2	36

#	Article	IF	Citations
109	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	1.3	36
110	NCCN Increases the Emphasis on Genetic/Familial High-Risk Assessment in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 829-831.	4.9	35
111	Origins and Prevalence of the American Founder Mutation of MSH2. Cancer Research, 2008, 68, 2145-2153.	0.9	34
112	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. International Journal of Cancer, 2019, 144, 2161-2168.	5.1	34
113	Identifying Lynch syndrome. International Journal of Cancer, 2009, 125, 1492-1493.	5.1	32
114	A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer. Gastroenterology, 2019, 157, 280-288.	1.3	32
115	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. JCO Precision Oncology, 2021, 5, 779-791.	3.0	31
116	The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. Genetics in Medicine, 2015, 17, 510-511.	2.4	30
117	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genetics in Medicine, 2016, 18, 863-868.	2.4	30
118	Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Medicine, 2022, 19, e1003897.	8.4	30
119	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	29
120	Variants in the Netrin-1 Receptor UNC5C Prevent Apoptosis and Increase Risk of Familial Colorectal Cancer. Gastroenterology, 2011, 141, 2039-2046.	1.3	28
121	Creation of a Network to Promote Universal Screening for Lynch Syndrome: The Lynch Syndrome Screening Network. Journal of Genetic Counseling, 2015, 24, 421-427.	1.6	28
122	Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. Human Pathology, 2018, 78, 125-130.	2.0	28
123	Mismatch Repair Protein Deficiency is Common in Sebaceous Neoplasms and Suggests the Importance of Screening for Lynch Syndrome. American Journal of Dermatopathology, 2013, 35, 191-195.	0.6	27
124	A Modified Lynch Syndrome Screening Algorithm in Colon Cancer. American Journal of Clinical Pathology, 2015, 143, 336-343.	0.7	27
125	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. American Journal of Clinical Nutrition, 2021, 113, 1490-1502.	4.7	27
126	Genetic Counseling Practice Analysis. Journal of Genetic Counseling, 2009, 18, 205-216.	1.6	26

#	Article	IF	Citations
127	Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies. Cancer Research, 2020, 80, 4578-4590.	0.9	26
128	Genotyping panel for assessing response to cancer chemotherapy. BMC Medical Genomics, 2008, 1, 24.	1.5	24
129	Characterization of the colorectal cancerâ€“associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genetics, 2012, 205, 25-33.	0.4	24
130	Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndromeâ€“Associated Neoplasms. American Journal of Clinical Pathology, 2016, 146, 50-56.	0.7	24
131	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecologic Oncology, 2021, 160, 161-168.	1.4	24
132	Genetic Testing for Hereditary Colorectal Cancer. Surgical Oncology Clinics of North America, 2009, 18, 687-703.	1.5	22
133	Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry. Archives of Pathology and Laboratory Medicine, 2018, 142, 523-528.	2.5	22
134	Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements. Cancer Research, 2002, 62, 4579-82.	0.9	22
135	Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. Public Health Genomics, 2018, 21, 121-132.	1.0	20
136	A High Percentage of Early-age Onset Colorectal Cancer Is Potentially Preventable. Gastroenterology, 2021, 160, 1850-1852.	1.3	19
137	Allele-specific expression of TGFBR1 in colon cancer patients. Carcinogenesis, 2010, 31, 1800-1804.	2.8	18
138	Phosphatase and Tensin Homolog Immunohistochemical Staining and Clinical Criteria for Cowden Syndrome in Patients With Trichilemmoma or Associated Lesions. American Journal of Dermatopathology, 2013, 35, 637-640.	0.6	18
139	Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?. Journal of Clinical Oncology, 2022, 40, 2681-2692.	1.6	18
140	MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas. Human Pathology, 2020, 96, 104-111.	2.0	17
141	What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?. Journal of Law and the Biosciences, 2020, 7, lsaa071.	1.6	17
142	American founder mutation for Lynch syndrome. Cancer, 2006, 106, 448-452.	4.1	16
143	Population Screening for Hereditary Colorectal Cancer. Surgical Oncology Clinics of North America, 2018, 27, 319-325.	1.5	15
144	Hereditary Colorectal Cancer Syndromes. Seminars in Oncology Nursing, 2019, 35, 58-78.	1.5	15

#	Article	IF	Citations
145	Early age onset colorectal cancer. Advances in Cancer Research, 2021, 151, 1-37.	5.0	15
146	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. JCO Precision Oncology, 2021, 5, 1588-1602.	3.0	15
147	Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. Familial Cancer, 2009, 8, 483-487.	1.9	14
148	Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome. Human Pathology, 2020, 103, 34-41.	2.0	14
149	Prevalence and Predictors of Young-Onset Colorectal Neoplasia: Insights From a Nationally Representative Colonoscopy Registry. Gastroenterology, 2022, 162, 1136-1146.e5.	1.3	14
150	Hereditary Colorectal Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 429-447.	2.2	14
151	Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs found in cancer patients. Human Mutation, 2012, 33, 1294-1301.	2.5	13
152	Preliminary validation of a consumer-oriented colorectal cancer risk assessment tool compatible with the US Surgeon Generalâ€™s My Family Health Portrait. Genetics in Medicine, 2015, 17, 753-756.	2.4	13
153	An American founder mutation in MLH1. International Journal of Cancer, 2012, 130, 2088-2095.	5.1	12
154	Stakeholder Perspectives on Overcoming Barriers to Cascade Testing in Lynch Syndrome: A Qualitative Study. Cancer Prevention Research, 2020, 13, 1037-1046.	1.5	12
155	Tumor Budding Detection System in Whole Slide Pathology Images. Journal of Medical Systems, 2020, 44, 38.	3.6	11
156	Patterns of Early-Onset Colorectal Cancer Among Nigerians and African Americans. JCO Global Oncology, 2020, 6, 1647-1655.	1.8	11
157	Recontacting Patients Who have Tested Negative for BRCA1 and BRCA2 Mutations: How, Who and Why?. Journal of Genetic Counseling, 2009, 18, 527-529.	1.6	10
158	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 564-575.	2.5	10
159	Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women. Familial Cancer, 2008, 7, 341-345.	1.9	9
160	Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterology, 2019, 6, e000299.	2.7	9
161	Comparative Effectiveness of Two Interventions to Increase Colorectal Cancer Screening for Those at Increased Risk Based on Family History: Results of a Randomized Trial. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 3-9.	2.5	9
162	Microsatellite instability in young patients with rectal cancer: molecular findings and treatment response. British Journal of Surgery, 2022, 109, 251-255.	0.3	9

#	Article	IF	Citations
163	Evaluation of Allele-Specific Somatic Changes of Genome-Wide Association Study Susceptibility Alleles in Human Colorectal Cancers. PLoS ONE, 2012, 7, e37672.	2.5	8
164	Cancer risks and mutation spectrum of mismatch repair genes in African American families with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 1530-1530.	1.6	8
165	Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Familial Cancer, 2018, 17, 431-434.	1.9	7
166	Modified captureâ€“recapture estimates of the number of families with Lynch syndrome in Central Ohio. Familial Cancer, 2019, 18, 67-73.	1.9	7
167	Risk assessment and genetic counseling for Lynch syndrome â€“ Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Journal of Genetic Counseling, 2022, 31, 568-583.	1.6	7
168	Impact of microsatellite status in early-onset colonic cancer. British Journal of Surgery, 2022, 109, 632-636.	0.3	7
169	Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Research and Treatment, 2022, 192, 639-648.	2.5	7
170	A 39-bp Deletion Polymorphism in PTEN in African American Individuals. Journal of Molecular Diagnostics, 2002, 4, 114-117.	2.8	6
171	Certified Genetic Counselors. Surgical Oncology Clinics of North America, 2015, 24, 653-666.	1.5	6
172	Stakeholdersâ€™ views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology. European Journal of Human Genetics, 2021, 29, 1634-1644.	2.8	6
173	Sarcoma: A Lynch syndrome (LS)-associated malignancy?. Journal of Clinical Oncology, 2015, 33, 1516-1516.	1.6	6
174	Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer. Journal of Personalized Medicine, 2021, 11, 1284.	2.5	6
175	Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1077-1089.	2.5	6
176	Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Familial Cancer, 2023, 22, 91-97.	1.9	6
177	Alleleâ€specific imbalance mapping at human orthologs of mouse susceptibility to colon cancer (Scc) loci. International Journal of Cancer, 2015, 137, 2323-2331.	5.1	5
178	Mutation Frequencies in Patients With Early-Onset Colorectal Cancerâ€”Reply. JAMA Oncology, 2017, 3, 1587.	7.1	5
179	Response to Li and Hopper. American Journal of Human Genetics, 2021, 108, 527-529.	6.2	5
180	American Gastroenterological Association Institute and College of American Pathologists Quality Measure Development for Detection of Mismatch Repair Deficiency and Lynch Syndrome Management. Gastroenterology, 2022, 162, 360-365.	1.3	4

#	Article	IF	Citations
181	PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.. Journal of Clinical Oncology, 2015, 33, 3550-3550.	1.6	4
182	Transition to the Clinical Doctorate: Attitudes of the Genetic Counseling Training Program Directors in North America. Journal of Genetic Counseling, 2012, 21, 136-149.	1.6	3
183	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. Human Genetics and Genomics Advances, 2020, 1, 100010.	1.7	3
184	Comprehensive population-wide detection of Lynch syndrome in Iceland.. Journal of Clinical Oncology, 2016, 34, 1542-1542.	1.6	3
185	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. Nutrients, 2021, 13, 4164.	4.1	3
186	Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients. Cancers, 2022, 14, 2426.	3.7	3
187	Advanced adenomas may be a red flag for hereditary cancer syndromes. Hereditary Cancer in Clinical Practice, 2021, 19, 8.	1.5	2
188	Utilizing Public Health Frameworks and Partnerships to Ensure Equity in DNA-Based Population Screening. Frontiers in Genetics, 2022, 13, .	2.3	2
189	Utilization of genetic counseling services by surgical oncologists: education a must. Clinical Genetics, 2006, 70, 524-525.	2.0	1
190	Reply to L.H. Jensen et al and S. Jahn et al. Journal of Clinical Oncology, 2009, 27, e225-e225.	1.6	1
191	MSH6 and PMS2 Mutation Carriers Ascertained Through Multi-gene Panel Testing May Present With a Hereditary Breast and Ovarian Cancer Phenotype. Gynecologic Oncology, 2016, 143, 194.	1.4	1
192	Implementing universal cancer screening programs can help sustain genomic medicine programs. Personalized Medicine, 2020, 17, 9-13.	1.5	1
193	Prostate cancer incidence in males with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 366-366.	1.6	1
194	Universal screening for Lynch syndrome (LS) in colorectal cancer (CRC) and survival.. Journal of Clinical Oncology, 2014, 32, 415-415.	1.6	1
195	A phase II study of PD-1 inhibition for the prevention of colon adenomas in patients with Lynch syndrome and a history of partial colectomy.. Journal of Clinical Oncology, 2019, 37, TPS1587-TPS1587.	1.6	1
196	Lynch Syndrome: Management of the Colon, What Operation?. , 2020, , 149-174.		1
197	Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1068-1076.	2.5	1
198	Universal tumor screening for lynch syndrome on colorectal cancer biopsies impacts surgical treatment decisions. Familial Cancer, 0, , .	1.9	1

#	Article	IF	Citations
199	Coming of Age in the Community Setting. Oncology Issues, 1999, 14, 14-15.	0.1	0
200	Compliance with recommended genetic counseling for Lynch syndrome: Room for improvement. Gynecologic Oncology, 2011, 120, S58-S59.	1.4	0
201	â€œHistology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndromeâ€â€”reply. Human Pathology, 2019, 89, 116-117.	2.0	0
202	Albert de la Chapelle (1933â€“2020). American Journal of Human Genetics, 2021, 108, 214-216.	6.2	0
203	Many Polyps but Few Referrals: A Call to Assess and Improve Referral Rates for Colon Polyposis. Diseases of the Colon and Rectum, 2021, 64, 1035-1037.	1.3	0
204	Prospective Evaluation of Mismatch Repair Protein Expression in Primary Colorectal Cancer. American Journal of Gastroenterology, 2008, 103, S169-S170.	0.4	0
205	Abstract 28: The Netrin-1 receptor UNC5C is a tumor suppressor in colorectal malignancies. , 2012, , .		0
206	Differences in outcome between colorectal cancer (CRC) patients (pts) with Lynch syndrome (LS) versus MLH1 hypermethylation (MLH1 HM).. Journal of Clinical Oncology, 2013, 31, 1556-1556.	1.6	0
207	Effect of genetic counseling on detection of Lynch syndrome (LS) in colorectal cancer (CRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 419-419.	1.6	0
208	Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147.. Journal of Clinical Oncology, 2016, 34, e15148-e15148.	1.6	0
209	Variable DNA mismatch repair-associated gene profiles in colorectal versus uterine cancers.. Journal of Clinical Oncology, 2017, 35, 11610-11610.	1.6	0
210	Screening for Pancreatic Cancer: Who to Screen and How to Follow-Up?. , 2018, , 97-108.		0
211	Prevalence of Mutations in Adenomatous Polyposis and Colorectal Cancer-Associated Genes in Patients With Multiple Colon Polyps Stratified by Age. American Journal of Gastroenterology, 2017, 112, S46-S47.	0.4	0
212	Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing.. Journal of Clinical Oncology, 2018, 36, e18705-e18705.	1.6	0
213	231â€ƒLow Prevalence of Gastric and Duodenal Neoplasia in Patients With Colon Polyposis of Unknown Etiology. American Journal of Gastroenterology, 2019, 114, S136-S136.	0.4	0
214	Tumor Budding Detection in H&E-Stained Images Using Deep Semantic Learning. , 2020, , .		0